Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Celgene Corporation : to Webcast at Upcoming Investor Conferences and Analyst Day

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/29/2013 | 02:40pm CEST

Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming investor conferences in May. The conferences will be webcast live and the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com. Celgene management will provide an overview of the Company.

Thursday, May 9, 2013 Celgene will present at Baird's 2013 Growth Stock Conference at 1:20 p.m. ET.

Thursday, May 16, 2013 Celgene will present at the 2013 Bank of America Merrill Lynch Global Healthcare Conference at 12:20 p.m. ET.

Wednesday, May 22, 2013 Celgene will present at the 2013 UBS Global Healthcare Conference at 11:30 a.m. ET.

Thursday, May 30, 2013 Celgene will present at Sanford C. Bernstein's 29th Annual Strategic Decisions Conference at 9:00 a.m. ET.

Additionally, Celgene plans to host an Analyst and Institutional Investor Day on May 6. The presentation will be webcast beginning at 1 p.m. ET and is expected to conclude at 5 p.m.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Celgene Corporation
Jacqualyn A. Fouse, Ph.D., 908-673-9956
EVP, Chief Financial Officer
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
04/21CELGENE SHAREHOLDER ALERT BY FORMER : Kahn Swick & Foti, LLC Reminds Investors ..
BU
04/20Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of Commenc..
BU
04/20CELGENE CORPORATION : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Rem..
AC
04/20CELGENE CORPORATION : to Webcast at Upcoming Investor Conferences
AQ
04/19BRAGAR EAGEL & SQUIRE, P.C. : Reminds Investors That a Class Action Lawsuit Has ..
BU
04/19CELGENE CORP /DE/ : Change in Directors or Principal Officers (form 8-K)
AQ
04/19CELGENE CORPORATION : Announces Changes to Its Board of Directors
BU
04/17CELGENE CORPORATION : to Webcast at Upcoming Investor Conferences
BU
04/13BEIGENE : Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in P..
AQ
04/13CELGENE : MorphoSys Nominates New Candidates for Supervisory Board
AQ
More news
News from SeekingAlpha
04/20PORTFOLIO STRATEGY REPORT : Why Investors Should Build Shares In Bioscience Stoc.. 
04/17Evelo Biosciences Files For U.S. IPO 
04/17PROJECT $1M : Q1 2018 Has Been A Rollercoaster Ride! 
04/17Wedgewood Partners Q1 2018 Client Letter - Hello Volatility, My Old Friend, I.. 
04/16Victory Formation Long/Short Portfolio Update - Buy Gold, Oil And Disney 
Financials ($)
Sales 2018 14 806 M
EBIT 2018 8 489 M
Net income 2018 5 310 M
Debt 2018 369 M
Yield 2018 -
P/E ratio 2018 13,01
P/E ratio 2019 10,82
EV / Sales 2018 4,54x
EV / Sales 2019 3,64x
Capitalization 66 906 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 116 $
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
Peter N. Kellogg Executive VP, Chief Financial & Accounting Officer
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Rupert J. Vessey President-Research & Early Development
Gilla Kaplan Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-14.12%66 906
JOHNSON & JOHNSON-8.71%339 783
PFIZER0.86%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
MERCK AND COMPANY4.55%158 571